Velzatinib demonstrates broad activity across KIT mutations in advanced gastrointestinal stromal tumours

Optimal panitumumab–bevacizumab sequencing evaluated in RAS wild-type metastatic colorectal cancer

Aspirin in stage III colorectal cancer shows no significant DFS benefit but favourable safety

Short-term fasting linked to improved chemo response in advanced ovarian cancer

FMISO PET-guided radiation dose de-escalation maintains long-term outcomes in HPV-associated oropharyngeal cancer

Amivantamab in HPV-unrelated mHNSCC gives high response rates after immunotherapy and chemo

Gene expression test guided therapy in ER+/HER2- early breast cancer allows safe chemotherapy omission

Tarlatamab in SCLC shows consistent effect and low immune toxicity across age groups

Adjuvant avelumab reduces relapse risk in stage III Merkel cell carcinoma

MCED blood test trial fails primary end point, but screening cut number of cancers found at stage IV

Fedratinib improves spleen and symptom responses with promising survival outcomes in MDS/MPN and CNL

177Lu-rosopatamab plus standard of care shows manageable safety and favourable tumour targeting in mCRPC